Achillion Pharmaceuticals (ACHN) : 9 analysts are covering Achillion Pharmaceuticals (ACHN) and their average rating on the stock is 2.33, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 2 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Achillion Pharmaceuticals (ACHN) : Average target price received by Achillion Pharmaceuticals (ACHN) is $10.11 with an expected standard deviation of $4.37. The most aggressive target on the stock is $17, whereas the most downbeat target is $4. 9 financial analysts are currently covering the stock.
Also, Chardan Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ:ACHN) The brokerage firm has issued a Sell rating on the shares. The Analysts at the ratings agency announces the price target to $4 per share. The rating by the firm was issued on July 14, 2016.
Achillion Pharmaceuticals (NASDAQ:ACHN): After opening at $8, the stock dipped to an intraday low of $7.88 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.32 and the buying power remained strong till the end. The stock closed at $8.06 for the day, a gain of 4.68% for the day session. The total traded volume was 4,344,332. The stocks close on the previous trading day was $7.7.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.